Dermapharm Holding SE: Continued Growth in Group Revenues and Group Adjusted EBITDA in 2022

0

DGAP-News: Dermapharm Holding SE / Keyword(s): Forecast

Dermapharm Holding SE: Continued Growth in Group Revenues and Group Adjusted EBITDA in 2022

29.03.2022 / 07:30
The issuer is solely responsible for the content of this announcement.

Dermapharm Holding SE: Continued Growth in Group Revenues and Group Adjusted EBITDA in 2022

The group’s turnover is expected to grow by 10% to 13% year-on-year

» Increase in the Group’s adjusted EBITDA by 3% to 7% compared to the previous year

» Additional revenue and profit contribution from the integration of the cannabis business

» Expanded vaccine cooperation with BioNTech SE

» Solid organic growth in the core business “Branded Pharmaceuticals”

Grünwald, March 29, 2022 – Dermapharm Holding SE (“Dermapharm”), a fast growing manufacturer of branded pharmaceuticals, expects continued growth in consolidated sales and adjusted consolidated EBITDA over the next the current 2022 financial year.

After the most successful fiscal year in the company’s 30-year history in 2021, the board expects continued growth despite global geopolitical and economic developments and the ongoing COVID-19 pandemic. To date, the Management Board expects the Group’s revenue for the 2022 financial year to grow within a range of 10% to 13% compared to the previous year. The Group’s adjusted EBITDA should increase in a range between 3% and 7% compared to the previous year.

In addition to the organic growth of the core business “Branded Pharmaceuticals”, the expansion of vaccine production in cooperation with BioNTech SE and the recently acquired cannabis business in the “Herbal Extracts” segment will make an important contribution to the growth of the current 2022 financial year. .

Dr. Hans-Georg Feldmeier, CEO of Dermapharm Holding SE: “Based on our robust and crisis-resistant business model, which is anchored in our broadly diversified product portfolio, we are able to react at short notice to changing market conditions. Marlet. current events in Ukraine, we are optimistic for the 2022 financial year. In the coming months, we will integrate the cannabis business into our group. The expected liberalization of the cannabis market also offers further growth potential.

Dermapharm will announce final audited figures for fiscal year 2021 along with the full 2021 Annual Report on April 12, 2022.

Company profile:

Dermapharm – Pharmaceutical Excellence “Made in Germany”

Dermapharm is a growing manufacturer of branded pharmaceuticals. Founded in 1991, the company is based in Grünwald near Munich. The company’s integrated business model includes in-house development, production and distribution of branded products by a trained pharmaceutical sales force. In addition to its main site in Brehna near Leipzig, Dermapharm also operates other production, development and distribution sites in Europe (mainly Germany) and the USA.

In the “Branded medicines and other health products” segment, Dermapharm has approximately 1,300 marketing authorizations with more than 380 active pharmaceutical ingredients. Dermapharm’s portfolio of pharmaceuticals, medical devices and dietary supplements is tailored to selected therapeutic areas in which the Company is a market leader, particularly in Germany.

In the “Plant extracts” segment, Dermapharm can rely on the expertise of the Spanish company Euromed SA, world leader in the manufacture of plant extracts and plant active ingredients for the pharmaceutical, nutraceutical, food and cosmetics industries. . Since the beginning of 2022, the segment has been completed by the German group C³, which develops, produces and markets natural and synthetic cannabinoids. The C³ group is the market leader for dronabinol in Germany and Austria.

Dermapharm’s business model also includes the “Parallel Import Business” segment which operates under the “axicorp” brand. Based on revenue, axicorp was among the top five parallel import companies in Germany in 2021.

With a consistent R&D strategy and numerous successful product and business acquisitions and intensifying its internationalization efforts, Dermapharm has continuously optimized its business over the past 30 years and sought out external growth opportunities. in addition to organic growth. Dermapharm is firmly committed to continuing on this path of profitable growth in the future.

Contact

Investor Relations and Corporate Communications
Britta Hamberger
Telephone: +49 (0)89 – 64186-233
Email: [email protected]

29.03.2022 Broadcast of a Corporate News, transmitted by the DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP distribution services include regulatory announcements, financial/corporate news and press releases.
Archive at www.dgap.de

Share.

Comments are closed.